Impact of Hyperuricemia on Psoriatic Arthritis

IImpact of Hyperuricemia on Psoriatic Arthritis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06125444

Acronym

Psoriatic

Enrollment

242

Registered

2023-11-09

Start date

2020-08-24

Completion date

2023-12-31

Last updated

2023-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Keywords

Psoriatic Arthritis, Hyperuricemia, Rheumatisms

Brief summary

Psoriatic arthritis and gout (linked to hyperuricemia) are two rheumatisms well known to rheumatologists. There are epidemiological and physiopathological arguments in favor of a non-fortuitous link between these two rheumatisms, which to date has not been established. There is currently no recommendation to treat hyperuricaemia without an episode of gout attack. We hypothesize that there is a link between hyperuricemia and severity of rheumatism. This would ultimately modify the therapeutic management of hyperuricemic patients followed for psoriatic arthritis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Major subject (≥18 years old) * Subject with a history of psoriatic arthritis objectified according to the CIM 10-1 coding for patients followed in hospitalization at the HUS and HCC * Subject presenting psoriatic arthritis objectified during a consultation by an HCC rheumatologist * Among these two populations, all subjects for whom at least one serum uric acid assay was available in the medical file * Subject having not expressed, after being informed, opposition to the reuse of their data for research purposes

Exclusion criteria

* Subject who expressed their opposition to participating in the study * Subject who met the inclusion criteria but whose analysis of the medical file (anamnestic, clinical, biological and radiological data) led to a diagnostic reversal and therefore did not present with psoriatic arthritis * Subject under guardianship or curatorship * Subject under safeguard of justice

Design outcomes

Primary

Measure	Time frame
Retrospectively determine the impact of hyperuricemia on the response to psoriatic arthritis treatments: inventory of the latest treatments in progress and the response to treatment according to the treating rheumatologist	Files analysed retrospectively from January 01, 2009 to December 31, 2019 will be examined

Countries

France

Contacts

Primary ContactRenaud FELTEN, MD

renaud.felten@chru-strasbourg.fr33 3 88 12 79 64

Outcome results